Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05169567 · MORE INFO

Limitations, agreements, and source contact

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer · Source last updated 2026-01-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
08005455979
title
Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
08005455979
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice